Eileen Wrabel

426 total citations
13 papers, 287 citations indexed

About

Eileen Wrabel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Eileen Wrabel has authored 13 papers receiving a total of 287 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in Eileen Wrabel's work include Advanced Breast Cancer Therapies (6 papers), HER2/EGFR in Cancer Research (6 papers) and Breast Cancer Treatment Studies (4 papers). Eileen Wrabel is often cited by papers focused on Advanced Breast Cancer Therapies (6 papers), HER2/EGFR in Cancer Research (6 papers) and Breast Cancer Treatment Studies (4 papers). Eileen Wrabel collaborates with scholars based in United States, Italy and Australia. Eileen Wrabel's co-authors include Ian E. Krop, Otto Metzger, Lorenzo Trippa, Kornélia Polyák, Giuseppe Viale, Eric P. Winer, Aditya Bardia, Laura M. Spring, Denise A. Yardley and Adrienne G. Waks and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Eileen Wrabel

11 papers receiving 282 citations

Peers

Eileen Wrabel

ONCOL

RNMI

PRM

Ottavia Amato Italy

Michelle K. DeMeo United States

Elisa Genovesi Italy

Vidyalakshmi Sethunath United States

Ning Liao China

P. Kaufman United States

Fanglei You United States

Julian Mangesius Austria

Myung Chang Lee United States

William Audeh United States

Ottavia Amato Italy

Eileen Wrabel

217 ×1.0

ONCOL

117 ×0.8

RNMI

123 ×1.7

78 ×1.3

PRM

39 ×0.8

Citations per year, relative to Eileen Wrabel Eileen Wrabel (= 1×) peers Ottavia Amato

Countries citing papers authored by Eileen Wrabel

Since Specialization

Citations

This map shows the geographic impact of Eileen Wrabel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eileen Wrabel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eileen Wrabel more than expected).

Fields of papers citing papers by Eileen Wrabel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eileen Wrabel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eileen Wrabel. The network helps show where Eileen Wrabel may publish in the future.

Co-authorship network of co-authors of Eileen Wrabel

This figure shows the co-authorship network connecting the top 25 collaborators of Eileen Wrabel. A scholar is included among the top collaborators of Eileen Wrabel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eileen Wrabel. Eileen Wrabel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Goel, Shom, Bojana Jovanović, Melissa E. Hughes, et al.. (2025). A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research. 31(8). 1427–1436. 3 indexed citations

Garrido-Castro, Ana C., Noah Graham, Lestat R. Ali, et al.. (2025). Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer. Journal for ImmunoTherapy of Cancer. 13(2). e010430–e010430. 5 indexed citations

Weiss, Anna, Qingchun Jin, Nabihah Tayob, et al.. (2025). Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial. Annals of Surgical Oncology. 33(3). 2275–2283.

Jin, Qingchun, Eileen Wrabel, Adrian Schubert, et al.. (2025). A phase 1b study of Plk1 inhibitor onvansertib in combination with paclitaxel in metastatic triple-negative breast cancer (mTNBC) patients.. Journal of Clinical Oncology. 43(16_suppl). 1100–1100.

Garrido-Castro, Ana C., Se Eun Kim, Rita Nanda, et al.. (2024). SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.. Journal of Clinical Oncology. 42(17_suppl). LBA1004–LBA1004. 20 indexed citations

Grinshpun, Albert, Shan Ren, Noah Graham, et al.. (2024). Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer. ESMO Open. 9(6). 103465–103465. 4 indexed citations

Metzger, Otto, Nabihah Tayob, Giuseppe Viale, et al.. (2024). Abstract PS09-02: Event-free Survival by Residual Cancer Burden (RCB) and Intratumor HER2 Heterogeneity after Neoadjuvant T-DM1 and Pertuzumab for Early-stage HER2-positive Breast Cancer. Cancer Research. 84(9_Supplement). PS09–2. 2 indexed citations

Zañudo, Jorge Gómez Tejeda, Romualdo Barroso‐Sousa, Esha Jain, et al.. (2024). Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nature Communications. 15(1). 2446–2446. 15 indexed citations

Goel, Shom, Bojana Jovanović, Melissa E. Hughes, et al.. (2024). Abstract PS12-06: A phase 2 study of abemaciclib monotherapy for patients with retinoblastoma-positive (Rb+), triple-negative metastatic breast cancer. Cancer Research. 84(9_Supplement). PS12–6. 1 indexed citations

10.

Weiss, Anna, Qingchun Jin, Adrienne G. Waks, et al.. (2023). Axillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical Trial. Journal of the American College of Surgeons. 238(3). 303–311. 2 indexed citations

11.

Metzger, Otto, Giuseppe Viale, Shayna Stein, et al.. (2021). Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discovery. 11(10). 2474–2487. 148 indexed citations

12.

Metzger, Otto, Giuseppe Viale, Lorenzo Trippa, et al.. (2019). HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.. Journal of Clinical Oncology. 37(15_suppl). 502–502. 67 indexed citations

13.

Wrabel, Eileen, et al.. (2014). Pathogen-inspired drug delivery to the central nervous system. Tissue Barriers. 2(4). e944449–e944449. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact